(Globe Newswire) Vancouver — Today Juva Life Inc., life science company with pharmaceutical and consumer-facing operations in the cannabis production and distribution space, highlights its financial results for Q1 of 2022.
$1.16 million of revenue was generated in Q1’22, nearly doubling the $.58 million of revenue from the same period in 2021. The growth was driven by increased sales in the retail business operations as well as the sale of wholesale bulk cannabis flower.
“As we move to the second half of the year, we are feeling extremely confident about our progress in both our life sciences research and cannabis operations. Our research team is moving at an unparalleled pace in proving the potential therapeutic value of both of our lead candidates, JUVA-019 and JUVA-041.” — Doug Chloupek, CEO and Founder of Juva
Print this page